News|Videos|October 8, 2026

PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews

API-gated journals may skew pharma regulatory research as AI agents favor accessible sources, raising citation integrity and pharmacovigilance risks.

As publishers and research platforms such as Reaxys and Springer Nature build application programming interface (API) access for AI tools, PharmTech AI Pulse Check panelists weigh whether evidence sitting outside those pipelines will quietly drop out of pharma's literature and regulatory research, and what that means for the citations companies put in front of regulators.

Related to this article

Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.